Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

10810	Companies
234079	Keywords
162831	Articles
125081	Press releases

Home
Companies
Biophytis

PRESS RELEASE

published on 06/10/2024 at 08:16, 2 years 1 month ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis submits IND application to US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone). Study to assess muscle strength & body composition. Research led by Professor Marc-André Cornier

Biophytis BIO101 IND Application Obesity Study Professor Marc-André Cornier
BRIEF

published on 06/07/2024 at 08:28, 2 years 1 month ago

Biophytis Announces Combined General Meeting on June 24, 2024

Shareholders Biophytis General Meeting Voting Agenda
REGULATED PRESS RELEASE

published on 06/07/2024 at 08:23, 2 years 1 month ago

Combined General Meeting of June 24, 2024
Biophytis SA to hold Combined General Meeting (CGM) on June 24, 2024 in Paris. Shareholders encouraged to vote in advance via multiple methods. Details available on the company's website

Shareholders Voting Combined General Meeting Biophytis SA CGM
BRIEF

published on 06/07/2024 at 07:44, 2 years 1 month ago

Biophytis Combined General Meeting scheduled for June 24, 2024

Shareholders Biophytis Paris General Assembly Vote
PRESS RELEASE

published on 06/07/2024 at 07:39, 2 years 1 month ago

Combined General Meeting of June 24, 2024
Biophytis to hold Combined General Meeting (CGM) on June 24, 2024 at Sorbonne Université. Shareholders urged to vote in advance. Company specializes in age-related disease therapeutics

Shareholders Biophytis Therapeutics Combined General Meeting Age-related Diseases
BRIEF

published on 05/14/2024 at 07:05, 2 years 2 months ago

Biophytis Unveils Phase 2 OBA Clinical Study Design in Obesity

Biophytis Obesity Treatment Clinical Trial BIO101 OBA Clinical Study
PRESS RELEASE

published on 05/14/2024 at 07:00, 2 years 2 months ago

Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), targeting muscle preservation in patients with obesity undergoing weight loss treatment with GLP-1 RAs

Biophytis BIO101 Muscle Preservation Obesity Phase 2 OBA Clinical Study
REGULATED PRESS RELEASE

published on 05/14/2024 at 07:00, 2 years 2 months ago

Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to test efficacy and safety for muscle function in obese patients. Study to start mid-2024 with results expected in 2025

Biophytis BIO101 Obesity Phase 2 OBA Clinical Study Muscle Function
BRIEF

published on 04/29/2024 at 14:44, 2 years 3 months ago

Biophytis announces the deployment of its partnership strategy in the obesity sector

Strategic Partnerships Biophytis Pharmaceutical BIO101 Obesity
PRESS RELEASE

published on 04/29/2024 at 14:39, 2 years 3 months ago

Biophytis is deploying its partnership strategy in obesity
Biophytis announces the implementation of a dedicated partnership strategy in obesity, aiming to collaborate with global pharmaceutical companies for drug development and commercialization. CEO Stanislas Veillet emphasizes the importance of addressing the obesity medical challenge through partnerships

Biophytis Drug Development Obesity Partnership Strategy Pharmaceutical Companies

Accesswire

Published on 08/06/2026 at 15:00, 3 hours 51 minutes ago

Norsemont Strategically Expands Choquelimpie Land Package To 9,048 Hectares
Published on 08/06/2026 at 14:30, 4 hours 21 minutes ago

Loar Holdings Inc. Reports Q2 2026 Record Results and Upward Revision to 2026 Outlook
Published on 08/06/2026 at 14:30, 4 hours 21 minutes ago

NV Gold Announces Expansion of Holdings and Drill Program at the Slumber Gold Project in Nevada
Published on 08/06/2026 at 14:30, 4 hours 21 minutes ago

AIAI Holdings' MediGuide Launches Longevity Intelligence, Redefining Personalized Preventive Healthcare
Published on 08/06/2026 at 14:00, 4 hours 51 minutes ago

Adcore to Publish Second Quarter 2026 Results on August 13, 2026

View all ACCESSWIRE

EQS Group

Published on 08/06/2026 at 18:24, 26 minutes ago

EQS-Adhoc: Allgeier SE: Allgeier Increases Revenue by 10 Percent in the First Half of 2026 and Confirms Its Guidance for 2026
Published on 08/06/2026 at 17:34, 1 hour 17 minutes ago

Issue of Equity
Published on 08/06/2026 at 17:20, 1 hour 31 minutes ago

Strutt Enters Europe: Expands Product Lineup with New ev¹e Variant and Showcases Evolving Smart Ecosystem at IFA 2026
Published on 08/06/2026 at 16:15, 2 hours 36 minutes ago

Monotype and Kittl Expand Partnership To Bring Brand Typography Directly Into Creative Workflows
Published on 08/06/2026 at 15:20, 3 hours 31 minutes ago

Form 8.3 - The Vanguard Group, Inc.: SEGRO plc

Les Echos

Published on 08/06/2026 at 18:26, 25 minutes ago

Air Liquide voting rights as of July 31st 2026
Published on 08/06/2026 at 17:45, 1 hour 6 minutes ago

Declaration of voting rights at the end of July 2026
Published on 08/06/2026 at 17:45, 1 hour 6 minutes ago

July 2026
Published on 08/06/2026 at 17:35, 1 hour 16 minutes ago

Groupe des Assurances du Crédit Mutuel (GACM)’s Solvency II ratio was 227% as of June 30, 2026
Published on 08/06/2026 at 17:35, 1 hour 16 minutes ago

Availability of the financial statements of Groupe des Assurances du Crédit Mutuel for the first half of 2026

View all LES ECHOS COMFI WIRE